The Cooper Companies (COO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

The Cooper Companies

NasdaqGS•Healthcare•Medical Instruments & Supplies

$53.78-0.83(-0.02%)After hours

Market Cap

$10.24B

P/E

18.0x

P/S

2.4x

P/B

1.2x

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How this company scores

ExcellentMetricSide Score: 85/100

Strongest: Cash & Earnings Quality (25/25); weakest: Growth (19/25).

Profitability19/25

Growth19/25

Balance Sheet & Red Flags22/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowRising earningsLow leverageInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.0x5y range 7.0x – 70.4x

Currently below its 20-quarter median.

P/S · 2.4x5y range 2.4x – 7.0x

Currently below its 20-quarter median.

P/B · 1.2x5y range 1.2x – 3.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 29.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $10.24B

Metrics at a Glance

as of July 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.24B
Q. Revenue: $1.07B
TTM EBITDA: $928.20M
TTM Op. Income: $544.20M
Q. Op. Income: $222.00M
TTM Net Income: $570.30M
Q. Net Income: $432.80M
EPS: $2.24
Shares Out.: $193.00M

$4.24B in TTM revenue grew 4.7% YoY, reaching $1.07B last quarter. TTM EBITDA of $928.20M and TTM operating income of $544.20M show growth is flowing through to the bottom line. TTM net income of $570.30M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 66.8%
EBITDA Margin: 29.7%
Op. Margin: 20.8%
Net Margin: 40.6%

Op. margin of 20.8% is up 4.3% YoY — cost efficiency is improving. Net margin at 40.6% and gross margin of 66.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 26% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 18.0x
P/S Ratio: 2.4x
P/B Ratio: 1.2x

At 18.0x P/E, the stock trades within typical market levels. P/S of 2.4x and P/B of 1.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 49% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $12.67B
Cash: $154.70M
Long-Term Debt: $1.91B
Book Value: $8.33B
D/E Ratio: 0.2
Debt/EBITDA: 6.0

With $12.67B in assets and $1.91B in long-term debt, D/E is 0.2and book value is $8.33B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $341.70M
TTM Free Cash Flow: $678.00M
FCF Margin: 16.0%
FCF / Net Income: 1.2

TTM FCF of $678.00M on $341.70M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.